Hannes Braberg

Hannes Braberg

Auto-generated profile, based on publicly available information

Hannes Braberg

QBI Coronavirus Research Group (QCRG), University of California San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DGDavid E. Gordon
David E. Gordon
GJGwendolyn M. Jang
Gwendolyn M. Jang
MBMehdi Bouhaddou
Mehdi Bouhaddou
JXJiewei Xu
Jiewei Xu
KOKirsten Obernier
Kirsten Obernier
NKNevan J. Krogan
Nevan J. Krogan

4 December 2020 in Science
Verified
Journal Article
Open access
PDF file
DGDavid E. Gordon
David E. Gordon
JHJoseph Hiatt
Joseph Hiatt
MBMehdi Bouhaddou
Mehdi Bouhaddou
VRVeronica V. Rezelj
Veronica V. Rezelj
SUSvenja Ulferts
Svenja Ulferts
HLHarris A. Lewin
Harris A. Lewin
How lethal coronaviruses engage hosts: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is closely related to the deadly coronaviruses SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV). Considerable efforts are focused on developing treatments, and therapies that work across coronaviruses would be particularly valuable. Shedding light on the host factors hijacked by the viruses, Gordon et al. mapped the interactions between viral and human proteins for SARS-CoV-2, SARS-CoV-1, and MERS-CoV; analyzed the localization of viral proteins in human cells; and used genetic screening to identify host factors that either enhance or inhibit viral infection. For a subset of the interactions essential for the virus life cycle, the authors determined the cryo–electron microscopy structures and mined patient data to understand how targeting host factors may be relevant to clinical outcomes. Science , this issue p. eabe9403

23 December 2021 in Nature
Verified
Journal Article
Open access
PDF file
LTLucy G. Thorne
Lucy G. Thorne
MBMehdi Bouhaddou
Mehdi Bouhaddou
ARAnn-Kathrin Reuschl
Ann-Kathrin Reuschl
LZLorena Zuliani-Alvarez
Lorena Zuliani-Alvarez
BPBen Polacco
Ben Polacco
NKNevan J. Krogan
Nevan J. Krogan
The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission1,2. Although much effort has focused on the characterization of changes in the spike protein in variants of concern, mutations outside of spike are likely to contribute to adaptation. Here, using unbiased abundance proteomics, phosphoproteomics, RNA sequencing and viral replication assays, we show that isolates of the Alpha (B.1.1.7) variant3suppress innate immune responses in airway epithelial cells more effectively than first-wave isolates. We found that the Alpha variant has markedly increased subgenomic RNA and protein levels of the nucleocapsid protein (N), Orf9b and Orf6—all known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein that is required for activation of the RNA-sensing adaptor MAVS. Moreover, the activity of Orf9b and its association with TOM70 was regulated by phosphorylation. We propose that more effective innate immune suppression, through enhanced expression of specific viral antagonist proteins, increases the likelihood of successful transmission of the Alpha variant, and may increase in vivo replication and duration of infection4. The importance of mutations outside the spike coding region in the adaptation of SARS-CoV-2 to humans is underscored by the observation that similar mutations exist in the N and Orf9b regulatory regions of the Delta and Omicron variants.

22 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DGDavid E. Gordon
David E. Gordon
GJGwendolyn M. Jang
Gwendolyn M. Jang
MBMehdi Bouhaddou
Mehdi Bouhaddou
JXJiewei Xu
Jiewei Xu
KOKirsten Obernier
Kirsten Obernier
MBMelanie Brewer
Melanie Brewer
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 67 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.

7 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LTLucy G Thorne
Lucy G Thorne
MBMehdi Bouhaddou
Mehdi Bouhaddou
ARAnn-Kathrin Reuschl
Ann-Kathrin Reuschl
LZLorena Zuliani-Alvarez
Lorena Zuliani-Alvarez
BPBen Polacco
Ben Polacco
NKNevan J. Krogan
Nevan J. Krogan
Emergence of SARS-CoV-2 variants, including the globally successful B.1.1.7 lineage, suggests viral adaptations to host selective pressures resulting in more efficient transmission. Although much effort has focused on Spike adaptation for viral entry and adaptive immune escape, B.1.1.7 mutations outside Spike likely contribute to enhance transmission. Here we used unbiased abundance proteomics, phosphoproteomics, mRNA sequencing and viral replication assays to show that B.1.1.7 isolates more effectively suppress host innate immune responses in airway epithelial cells. We found that B.1.1.7 isolates have dramatically increased subgenomic RNA and protein levels of Orf9b and Orf6, both known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein required for RNA sensing adaptor MAVS activation, and Orf9b binding and activity was regulated via phosphorylation. We conclude that B.1.1.7 has evolved beyond the Spike coding region to more effectively antagonise host innate immune responses through upregulation of specific subgenomic RNA synthesis and increased protein expression of key innate immune antagonists. We propose that more effective innate immune antagonism increases the likelihood of successful B.1.1.7 transmission, and may increase in vivo replication and duration of infection.

27 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKelsey M. Haas
Kelsey M. Haas
MMMichael J. McGregor
Michael J. McGregor
MBMehdi Bouhaddou
Mehdi Bouhaddou
BPBenjamin J. Polacco
Benjamin J. Polacco
EKEun-Young Kim
Eun-Young Kim
NKNevan J. Krogan
Nevan J. Krogan
Influenza A Virus (IAV) is a recurring respiratory virus with limited availability of antiviral therapies. Understanding host proteins essential for IAV infection can identify targets for alternative host-directed therapies (HDTs). Using affinity purification-mass spectrometry and global phosphoproteomic and protein abundance analyses using three IAV strains (pH1N1, H3N2, H5N1) in three human cell types (A549, NHBE, THP-1), we map 332 IAV-human protein-protein interactions and identify 13 IAV-modulated kinases. Whole exome sequencing of patients who experienced severe influenza reveals several genes, including scaffold protein AHNAK, with predicted loss-of-function variants that are also identified in our proteomic analyses. Of our identified host factors, 54 significantly alter IAV infection upon siRNA knockdown, and two factors, AHNAK and coatomer subunit COPB1, are also essential for productive infection by SARS-CoV-2. Finally, 16 compounds targeting our identified host factors suppress IAV replication, with two targeting CDK2 and FLT3 showing pan-antiviral activity across influenza and coronavirus families. This study provides a comprehensive network model of IAV infection in human cells, identifying functional host targets for pan-viral HDT.